The World Health Organization recommends Paxlovid, a combination of nirmatrelivir and ritonavir, over remdesivir, molnupiravir and monoclonal antibodies for those with COVID-19 who are unvaccinated, older or immunocompromised. The recommendation was announced in The BMJ and based on findings from two clinical trials showing that Paxlovid reduced the risk of hospitalization by 85%.
Full Story: Medical Dialogues (4/22)